Even more schizophrenia patients only get a partial benefit from existing medicines or cant handle them because of side effects. Doctors are eager for alternative treatments and appear to view the KarXT data favorably according to RBCs Abrahams. He expects the medicine to win approval and bring in peak sales of 12 billion